In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
The historic rise of rental costs in Canada
How an Ontario city is taking a new approach to homelessness
The Canadian scientist at the centre of the OpenAI drama
Gaza’s underground tunnels
What’s behind the shakeup of Alberta’s health care system
A new twist in the two Michaels saga
The newest nicotine product to spark old fears
After 144 years, bringing home remains from a residential school
The life-or-death limbo of the Afghans who helped Canada
Qatar’s behind-the-scenes role in the Israel-Hamas war
How climate change clues are frozen in glaciers
Quebec targets out-of-province students with big tuition hikes
Canada’s broken information laws keep history in the dark
What students think about the parents’ rights movement
Canada’s billion-dollar wine industry is changing. Here’s why
Why the ‘lottery’ of Canadian immigration undermines the system
The battle over the future of the Banff arts centre
A ‘balance of terror’: The geopolitics of the Israel-Hamas war
Premiers attack Trudeau after carbon tax carve-out
Voices inside Gaza and Israel, in the ‘second stage’ of war
Create your
podcast in
minutes
It is Free
As It Happens
The Daily
Morning Wire
Up First
Dobré ráno | Denný podcast denníka SME